Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome

OBJECTIVES: To assess the outcomes of pediatric patients with laboratory-confirmed coronavirus disease (COVID-19) with or without multisystem inflammatory syndrome in children (MIS-C). METHODS: This cross-sectional study included 471 samples collected from 371 patients (age<18 years) suspected of having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study group comprised 66/371 (18%) laboratory-confirmed pediatric COVID-19 patients: 61 (92.5%) patients tested positive on real-time reverse transcription-polymerase chain reaction tests for SARS-CoV-2, and 5 (7.5%) patients tested positive on serological tests. MIS-C was diagnosed according to the criteria of the Center for Disease Control. RESULTS: MIS-C was diagnosed in 6/66 (9%) patients. The frequencies of diarrhea, vomiting, and/or abdominal pain (67% vs. 22%, p=0.034); pediatric SARS (67% vs. 13%, p=0.008); hypoxemia (83% vs. 23%, p=0.006); and arterial hypotension (50% vs. 3%, p=0.004) were significantly higher in patients with MIS-C than in those without MIS-C. The frequencies of C-reactive protein levels >50 mg/L (83% vs. 25%, p=0.008) and D-dimer levels >1000 ng/mL (100% vs. 40%, p=0.007) and the median D-dimer, troponin T, and ferritin levels (p<0.05) were significantly higher in patients with MIS-C. The frequencies of pediatric intensive care unit admission (100% vs. 60%, p=0.003), mechanical ventilation (83% vs. 7%, p<0.001), vasoactive agent use (83% vs. 3%, p<0.001), shock (83% vs. 5%, p<0.001), cardiac abnormalities (100% vs. 2%, p<0.001), and death (67% vs. 3%, p<0.001) were also significantly higher in patients with MIS-C. Similarly, the frequencies of oxygen therapy (100% vs. 33%, p=0.003), intravenous immunoglobulin therapy (67% vs. 2%, p<0.001), aspirin therapy (50% vs. 0%, p<0.001), and current acute renal replacement therapy (50% vs. 2%, p=0.002) were also significantly higher in patients with MIS-C. Logistic regression analysis showed that the presence of MIS-C was significantly associated with gastrointestinal manifestations [odds ratio (OR)=10.98; 95%CI (95% confidence interval)=1.20-100.86; p=0.034] and hypoxemia [OR=16.85; 95%CI=1.34-211.80; p=0.029]. Further univariate analysis showed a positive association between MIS-C and death [OR=58.00; 95%CI=6.39-526.79; p<0.0001]. CONCLUSIONS: Pediatric patients with laboratory-confirmed COVID-19 with MIS-C had a severe clinical spectrum with a high mortality rate. Our study emphasizes the importance of investigating MIS-C in pediatric patients with COVID-19 presenting with gastrointestinal involvement and hypoxemia.

Saved in:
Bibliographic Details
Main Authors: Pereira,Maria Fernanda Badue, Litvinov,Nadia, Farhat,Sylvia Costa Lima, Eisencraft,Adriana Pasmanik, Gibelli,Maria Augusta Bento Cicaroni, Carvalho,Werther Brunow de, Fernandes,Vinicius Rodrigues, Fink,Thais de Toledo, Framil,Juliana Valéria de Souza, Galleti,Karine Vusberg, Fante,Alice Lima, Fonseca,Maria Fernanda Mota, Watanabe,Andreia, Paula,Camila Sanson Yoshino de, Palandri,Giovanna Gavros, Leal,Gabriela Nunes, Diniz,Maria de Fatima Rodrigues, Pinho,João Renato Rebello, Silva,Clovis Artur, Marques,Heloisa Helena de Sousa, Rossi Junior,Alfio, Delgado,Artur Figueiredo, Andrade,Anarella Penha Meirelles de, Schvartsman,Claudio, Sabino,Ester Cerdeira, Rocha,Mussya Cisotto, Kanunfre,Kelly Aparecida, Okay,Thelma Suely, Carneiro-Sampaio,Magda Maria Sales, Jorge,Patricia Palmeira Daenekas
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322020000100263
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322020000100263
record_format ojs
spelling oai:scielo:S1807-593220200001002632020-08-17Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndromePereira,Maria Fernanda BadueLitvinov,NadiaFarhat,Sylvia Costa LimaEisencraft,Adriana PasmanikGibelli,Maria Augusta Bento CicaroniCarvalho,Werther Brunow deFernandes,Vinicius RodriguesFink,Thais de ToledoFramil,Juliana Valéria de SouzaGalleti,Karine VusbergFante,Alice LimaFonseca,Maria Fernanda MotaWatanabe,AndreiaPaula,Camila Sanson Yoshino dePalandri,Giovanna GavrosLeal,Gabriela NunesDiniz,Maria de Fatima RodriguesPinho,João Renato RebelloSilva,Clovis ArturMarques,Heloisa Helena de SousaRossi Junior,AlfioDelgado,Artur FigueiredoAndrade,Anarella Penha Meirelles deSchvartsman,ClaudioSabino,Ester CerdeiraRocha,Mussya CisottoKanunfre,Kelly AparecidaOkay,Thelma SuelyCarneiro-Sampaio,Magda Maria SalesJorge,Patricia Palmeira Daenekas COVID-19 Children Adolescent Outcome, Immunosuppression Multisystem Inflammatory Syndrome OBJECTIVES: To assess the outcomes of pediatric patients with laboratory-confirmed coronavirus disease (COVID-19) with or without multisystem inflammatory syndrome in children (MIS-C). METHODS: This cross-sectional study included 471 samples collected from 371 patients (age<18 years) suspected of having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study group comprised 66/371 (18%) laboratory-confirmed pediatric COVID-19 patients: 61 (92.5%) patients tested positive on real-time reverse transcription-polymerase chain reaction tests for SARS-CoV-2, and 5 (7.5%) patients tested positive on serological tests. MIS-C was diagnosed according to the criteria of the Center for Disease Control. RESULTS: MIS-C was diagnosed in 6/66 (9%) patients. The frequencies of diarrhea, vomiting, and/or abdominal pain (67% vs. 22%, p=0.034); pediatric SARS (67% vs. 13%, p=0.008); hypoxemia (83% vs. 23%, p=0.006); and arterial hypotension (50% vs. 3%, p=0.004) were significantly higher in patients with MIS-C than in those without MIS-C. The frequencies of C-reactive protein levels >50 mg/L (83% vs. 25%, p=0.008) and D-dimer levels >1000 ng/mL (100% vs. 40%, p=0.007) and the median D-dimer, troponin T, and ferritin levels (p<0.05) were significantly higher in patients with MIS-C. The frequencies of pediatric intensive care unit admission (100% vs. 60%, p=0.003), mechanical ventilation (83% vs. 7%, p<0.001), vasoactive agent use (83% vs. 3%, p<0.001), shock (83% vs. 5%, p<0.001), cardiac abnormalities (100% vs. 2%, p<0.001), and death (67% vs. 3%, p<0.001) were also significantly higher in patients with MIS-C. Similarly, the frequencies of oxygen therapy (100% vs. 33%, p=0.003), intravenous immunoglobulin therapy (67% vs. 2%, p<0.001), aspirin therapy (50% vs. 0%, p<0.001), and current acute renal replacement therapy (50% vs. 2%, p=0.002) were also significantly higher in patients with MIS-C. Logistic regression analysis showed that the presence of MIS-C was significantly associated with gastrointestinal manifestations [odds ratio (OR)=10.98; 95%CI (95% confidence interval)=1.20-100.86; p=0.034] and hypoxemia [OR=16.85; 95%CI=1.34-211.80; p=0.029]. Further univariate analysis showed a positive association between MIS-C and death [OR=58.00; 95%CI=6.39-526.79; p<0.0001]. CONCLUSIONS: Pediatric patients with laboratory-confirmed COVID-19 with MIS-C had a severe clinical spectrum with a high mortality rate. Our study emphasizes the importance of investigating MIS-C in pediatric patients with COVID-19 presenting with gastrointestinal involvement and hypoxemia.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.75 20202020-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322020000100263en10.6061/clinics/2020/e2209
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Pereira,Maria Fernanda Badue
Litvinov,Nadia
Farhat,Sylvia Costa Lima
Eisencraft,Adriana Pasmanik
Gibelli,Maria Augusta Bento Cicaroni
Carvalho,Werther Brunow de
Fernandes,Vinicius Rodrigues
Fink,Thais de Toledo
Framil,Juliana Valéria de Souza
Galleti,Karine Vusberg
Fante,Alice Lima
Fonseca,Maria Fernanda Mota
Watanabe,Andreia
Paula,Camila Sanson Yoshino de
Palandri,Giovanna Gavros
Leal,Gabriela Nunes
Diniz,Maria de Fatima Rodrigues
Pinho,João Renato Rebello
Silva,Clovis Artur
Marques,Heloisa Helena de Sousa
Rossi Junior,Alfio
Delgado,Artur Figueiredo
Andrade,Anarella Penha Meirelles de
Schvartsman,Claudio
Sabino,Ester Cerdeira
Rocha,Mussya Cisotto
Kanunfre,Kelly Aparecida
Okay,Thelma Suely
Carneiro-Sampaio,Magda Maria Sales
Jorge,Patricia Palmeira Daenekas
spellingShingle Pereira,Maria Fernanda Badue
Litvinov,Nadia
Farhat,Sylvia Costa Lima
Eisencraft,Adriana Pasmanik
Gibelli,Maria Augusta Bento Cicaroni
Carvalho,Werther Brunow de
Fernandes,Vinicius Rodrigues
Fink,Thais de Toledo
Framil,Juliana Valéria de Souza
Galleti,Karine Vusberg
Fante,Alice Lima
Fonseca,Maria Fernanda Mota
Watanabe,Andreia
Paula,Camila Sanson Yoshino de
Palandri,Giovanna Gavros
Leal,Gabriela Nunes
Diniz,Maria de Fatima Rodrigues
Pinho,João Renato Rebello
Silva,Clovis Artur
Marques,Heloisa Helena de Sousa
Rossi Junior,Alfio
Delgado,Artur Figueiredo
Andrade,Anarella Penha Meirelles de
Schvartsman,Claudio
Sabino,Ester Cerdeira
Rocha,Mussya Cisotto
Kanunfre,Kelly Aparecida
Okay,Thelma Suely
Carneiro-Sampaio,Magda Maria Sales
Jorge,Patricia Palmeira Daenekas
Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome
author_facet Pereira,Maria Fernanda Badue
Litvinov,Nadia
Farhat,Sylvia Costa Lima
Eisencraft,Adriana Pasmanik
Gibelli,Maria Augusta Bento Cicaroni
Carvalho,Werther Brunow de
Fernandes,Vinicius Rodrigues
Fink,Thais de Toledo
Framil,Juliana Valéria de Souza
Galleti,Karine Vusberg
Fante,Alice Lima
Fonseca,Maria Fernanda Mota
Watanabe,Andreia
Paula,Camila Sanson Yoshino de
Palandri,Giovanna Gavros
Leal,Gabriela Nunes
Diniz,Maria de Fatima Rodrigues
Pinho,João Renato Rebello
Silva,Clovis Artur
Marques,Heloisa Helena de Sousa
Rossi Junior,Alfio
Delgado,Artur Figueiredo
Andrade,Anarella Penha Meirelles de
Schvartsman,Claudio
Sabino,Ester Cerdeira
Rocha,Mussya Cisotto
Kanunfre,Kelly Aparecida
Okay,Thelma Suely
Carneiro-Sampaio,Magda Maria Sales
Jorge,Patricia Palmeira Daenekas
author_sort Pereira,Maria Fernanda Badue
title Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome
title_short Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome
title_full Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome
title_fullStr Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome
title_full_unstemmed Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome
title_sort severe clinical spectrum with high mortality in pediatric patients with covid-19 and multisystem inflammatory syndrome
description OBJECTIVES: To assess the outcomes of pediatric patients with laboratory-confirmed coronavirus disease (COVID-19) with or without multisystem inflammatory syndrome in children (MIS-C). METHODS: This cross-sectional study included 471 samples collected from 371 patients (age<18 years) suspected of having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study group comprised 66/371 (18%) laboratory-confirmed pediatric COVID-19 patients: 61 (92.5%) patients tested positive on real-time reverse transcription-polymerase chain reaction tests for SARS-CoV-2, and 5 (7.5%) patients tested positive on serological tests. MIS-C was diagnosed according to the criteria of the Center for Disease Control. RESULTS: MIS-C was diagnosed in 6/66 (9%) patients. The frequencies of diarrhea, vomiting, and/or abdominal pain (67% vs. 22%, p=0.034); pediatric SARS (67% vs. 13%, p=0.008); hypoxemia (83% vs. 23%, p=0.006); and arterial hypotension (50% vs. 3%, p=0.004) were significantly higher in patients with MIS-C than in those without MIS-C. The frequencies of C-reactive protein levels >50 mg/L (83% vs. 25%, p=0.008) and D-dimer levels >1000 ng/mL (100% vs. 40%, p=0.007) and the median D-dimer, troponin T, and ferritin levels (p<0.05) were significantly higher in patients with MIS-C. The frequencies of pediatric intensive care unit admission (100% vs. 60%, p=0.003), mechanical ventilation (83% vs. 7%, p<0.001), vasoactive agent use (83% vs. 3%, p<0.001), shock (83% vs. 5%, p<0.001), cardiac abnormalities (100% vs. 2%, p<0.001), and death (67% vs. 3%, p<0.001) were also significantly higher in patients with MIS-C. Similarly, the frequencies of oxygen therapy (100% vs. 33%, p=0.003), intravenous immunoglobulin therapy (67% vs. 2%, p<0.001), aspirin therapy (50% vs. 0%, p<0.001), and current acute renal replacement therapy (50% vs. 2%, p=0.002) were also significantly higher in patients with MIS-C. Logistic regression analysis showed that the presence of MIS-C was significantly associated with gastrointestinal manifestations [odds ratio (OR)=10.98; 95%CI (95% confidence interval)=1.20-100.86; p=0.034] and hypoxemia [OR=16.85; 95%CI=1.34-211.80; p=0.029]. Further univariate analysis showed a positive association between MIS-C and death [OR=58.00; 95%CI=6.39-526.79; p<0.0001]. CONCLUSIONS: Pediatric patients with laboratory-confirmed COVID-19 with MIS-C had a severe clinical spectrum with a high mortality rate. Our study emphasizes the importance of investigating MIS-C in pediatric patients with COVID-19 presenting with gastrointestinal involvement and hypoxemia.
publisher Faculdade de Medicina / USP
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322020000100263
work_keys_str_mv AT pereiramariafernandabadue severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT litvinovnadia severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT farhatsylviacostalima severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT eisencraftadrianapasmanik severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT gibellimariaaugustabentocicaroni severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT carvalhowertherbrunowde severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT fernandesviniciusrodrigues severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT finkthaisdetoledo severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT framiljulianavaleriadesouza severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT galletikarinevusberg severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT fantealicelima severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT fonsecamariafernandamota severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT watanabeandreia severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT paulacamilasansonyoshinode severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT palandrigiovannagavros severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT lealgabrielanunes severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT dinizmariadefatimarodrigues severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT pinhojoaorenatorebello severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT silvaclovisartur severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT marquesheloisahelenadesousa severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT rossijunioralfio severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT delgadoarturfigueiredo severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT andradeanarellapenhameirellesde severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT schvartsmanclaudio severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT sabinoestercerdeira severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT rochamussyacisotto severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT kanunfrekellyaparecida severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT okaythelmasuely severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT carneirosampaiomagdamariasales severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
AT jorgepatriciapalmeiradaenekas severeclinicalspectrumwithhighmortalityinpediatricpatientswithcovid19andmultisysteminflammatorysyndrome
_version_ 1756432355228123136